Literature DB >> 15821481

Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection.

Saadettin Yilmaz Eskicorapci1, Fuad Guliyev, Bulent Akdogan, Hasan Serkan Dogan, Ali Ergen, Haluk Ozen.   

Abstract

PURPOSE: In this study we assessed the relative yield of 10 core biopsy, and the whole range of alternative 8 and 6 core biopsy protocols over that of the classic sextant biopsy protocol. We determined the optimum number of cores per biopsy according to prostate volume in patients who experienced prostate biopsy for the first time.
MATERIALS AND METHODS: A total of 503 men with the indications of abnormal digital rectal examination and/or serum prostate specific antigen greater than 2.5 ng/ml were included in the study. All patients underwent a 10 core biopsy protocol with an additional 1 core from each suspicious area detected by transrectal ultrasound. Prostate volume was divided into quartiles, namely 14.9 to 35, 35.1 to 50, 50.1 to 65 and 65.1 to 150 cc. The optimum number of biopsy cores was determined in patients with different prostate volumes.
RESULTS: Median age was 63 years and prostate specific antigen was 7.4 ng/ml in the whole group. Of 503 patients 159 (31.6%) were positive for prostate cancer. Cancer detection rates decreased significantly from 49.6% to 20.8% as prostate volume increased in preset quartiles. Lesion biopsies revealed the lowest unique cancer detection rates for all prostate volume quartiles (0% to 3%). There was an obvious positive trend in cancer detection rates in favor of the 10 core biopsy protocol over sextant biopsies in all patient groups. Classic sextant biopsy protocol proved to be inadequate for all prostate volumes. Among sextant biopsy protocols laterally placed cores including the apex, lateral mid gland and lateral base had the best cancer detection rates (81% to 95%). The 8 core biopsy scheme consisting of the apex, mid gland, lateral mid gland and lateral base resulted in an only 1% lower detection rate (97%) than the 10 core biopsy protocol in the lowest quartile. The yield of the 10 core biopsy protocol in patients with a prostate volume of between 35.1 and 150 cc outscored that of the optimal 8 core biopsy scheme including the apex, base, lateral mid gland and lateral base with 3% to 8% differences in the cancer detection rate.
CONCLUSIONS: The 10 core biopsy protocol must be used in all group of patients except patients with a prostate volume of 14.9 to 35 cc. In patients with a prostate volume of 14.9 to 35 cc the 8 core biopsy protocol consisting of the apex, mid gland, lateral mid gland and lateral base can be used since it revealed results similar to those of the 10 core biopsy protocol. The classic sextant biopsy protocol seemed inadequate for all prostate volumes. Patients with a larger prostate had lower cancer detection rates. Transrectal ultrasound directed lesion biopsies may be omitted when using 10 core biopsy protocols since the yield of these biopsies was less than 2%.

Entities:  

Mesh:

Year:  2005        PMID: 15821481     DOI: 10.1097/01.ju.0000154242.60413.3d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes.

Authors:  Julie C Bulman; Robert Toth; Amish D Patel; B Nicolas Bloch; Colm J McMahon; Long Ngo; Anant Madabhushi; Neil M Rofsky
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

2.  Advantages of single-puncture transperineal saturation biopsy of prostate: analysis of outcomes in 125 patients using our scheme.

Authors:  Eugenio Martorana; Salvatore Micali; Ahmed Ghaith; Luca Reggiani Bonetti; Maria Chiara Sighinolfi; Riccardo Galli; Maurizio Paterlini; Giampaolo Bianchi
Journal:  Int Urol Nephrol       Date:  2015-04-08       Impact factor: 2.370

3.  The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique.

Authors:  Saadettin Yilmaz Eskicorapci; Fuad Guliyev; Ekrem Islamoglu; Ali Ergen; Haluk Ozen
Journal:  Int Urol Nephrol       Date:  2006-06-01       Impact factor: 2.370

4.  How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?

Authors:  Ege Can Serefoglu; Serkan Altinova; Nevzat Serdar Ugras; Egemen Akincioglu; Erem Asil; M Derya Balbay
Journal:  Can Urol Assoc J       Date:  2013-05-13       Impact factor: 1.862

5.  The impact of core biopsy fragmentation in prostate cancer.

Authors:  Leonardo Oliveira Reis; José Alberto Salvo Reinato; Daniel Carlos Silva; Wagner Eduardo Matheus; Fernandes Denardi; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2010-03-11       Impact factor: 2.370

6.  Is sampling transitional zone in patients who had prior negative prostate biopsy necessary?

Authors:  Bayram Dogan; Ege Can Serefoglu; Ali Fuat Atmaca; Abdullah Erdem Canda; Ziya Akbulut; M Derya Balbay
Journal:  Int Urol Nephrol       Date:  2012-03-15       Impact factor: 2.370

7.  The importance of prostate volume in prostate needle biopsy.

Authors:  Ömer Gökhan Doluoğlu; Çetin Volkan Öztekin; Mehmet Karabakan; Alp Özgür Akdemir; Mesut Çetinkaya
Journal:  Turk J Urol       Date:  2013-06

8.  Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings.

Authors:  Philip Quann; David F Jarrard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2010-03-30

Review 9.  Any Correlation Between Prostate Volume and Incidence of Prostate Cancer: A Review of Reported Data for the Last Thirty Years.

Authors:  Justine R Yamashiro; Werner T W de Riese
Journal:  Res Rep Urol       Date:  2021-10-10

10.  DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy.

Authors:  A Paziewska; M Dabrowska; K Goryca; A Antoniewicz; J Dobruch; M Mikula; D Jarosz; L Zapala; A Borowka; J Ostrowski
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.